Paclitaxel not without limits

Beyond its role as a cancer agent, researchers believe paclitaxel has potential to treat a variety of autoimmune and inflammatory disorders based on its inhibition of the AP-1 transcription factor. However, the prospects of the compound in such areas may be limited. Last week, Angiotech Pharmaceuticals Inc. decided to end development of its Paxceed micellar formulation in multiple sclerosis, although the company said it will continue clinical testing in psoriasis and rheumatoid arthritis.

The decision by Angiotech (ANPI; TSE:ANP, Vancouver, B.C.) was based on data from a Canadian Phase II trial in 174 patients, in which Paxceed failed to meet the primary endpoint of a difference in new lesion activity versus controls (see B9). ...